SM
AGIO icon

Sabby Management’s Agios Pharmaceuticals AGIO Stock Holding History

Sabby Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-109,521
Closed -$7.73M – 319
2015
Q3 		$7.73M Buy
+109,521
New +$10.7M 0.32% 50
2015
Q2 		– Sell
-3,163
Closed -$341K – 323
2015
Q1 		$298K Buy
+3,163
New +$354K 0.01% 251

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Sabby Management's AGIO Position: Q4 2015 in Review

Sabby Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2015, closing a stake of 109,521 shares — an estimated $7.73M sold.

Sabby Management first reported a position in AGIO in Q1 2015 and held it in 2 quarters. The position peaked at $7.73M in Q3 2015. 144 funds tracked by Wall St. Rank hold AGIO as of Q4 2015.

  • Sabby Management reported no remaining Agios Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Sabby Management sold 109,521 Agios Pharmaceuticals shares in Q4 2015, an estimated $7.73M.
  • Sabby Management first reported a position in Agios Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Sabby Management's Agios Pharmaceuticals position peaked at $7.73M in Q3 2015.
  • 144 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.